Driving the discovery, development, and commercialization of groundbreaking therapies through innovative science.

Our mission is to eliminate inaccuracy and waste when translating drug candidates to clinical trials using AI-driven, multi-disciplinary quantitative methods that predict patient outcomes.

What if?

• The lead compound with most confidence could be identified early
• You know which drug candidates not to pursue further
• Resources, dollars and expertise were allocated only to the promising candidates
• You could save years of back and forth with regulators when trying to get a drug to market

Introducing a first-in-class decision engine that enables AI drug discovery and R&D de-risking, unlike anything you’ve worked with before.

Inferential search space of 1 billion drug-like compounds

10 billion network effects spawned in deep learning algorithms

800 billion total potential simulation scenarios computational capacity

1.5 million real and robust validation simulations

83% average accuracy predictions from structure only

Trusted by leaders in pharmaceutical research and development

BIOiSIM-accelerated assets in pipeline

Our AI-driven drug development services deliver insights for pharmaceutical companies, biotechs, and academic & research institutions. We also partner in risk-sharing collaborations to develop promising drugs.

PulmoSIM Therapeutics, a wholly-owned brand of VeriSIM Life, identifies licensable candidates for preclinical translation and out-licensing to commercialization partners.

Making a difference

Addressing the unmet needs of patients everywhere is our passion. Are you motivated by ownership in your work and a mission to make a difference? Do you embrace diversity? Is continuous learning part of your DNA? This is what drives the team at VeriSIM Life every day.

News and events

• VeriSIM Life Awarded NIH Phase II STTR to Advance AI Driven Drug Discovery Platform
• VeriSIM Life Formalizes Research Collaboration with FDA/NCTR, Advancing the Next Generation of Mechanistic AI for Drug Development
• VeriSIM Life Founder & CEO Dr. Jo Varshney Named to Inc.’s Female Founders 500 for Advancing Predictive Drug Development

BIOiSIM is a decision-making engine that can take your toughest translational questions and generate actionable insights to guide your next steps. Our unified framework combines chemical and biological modeling along with AI and ML techniques and data to provide a Translational Index™ predicting how drugs will affect patients, to optimize portfolio management and increase clinical success. Read our published scientific research.